MEDIR is a specialty pharmaceutical company, seeking to address the areas of high unmet medical needs in:
1. inducing mild sedation in a safe, convenient and needle free way; and
2. offering a treatment for acute epileptic seizure control outside a hospital setting, that is fast, efficacious and easy adminstered.
The company has developed nasal sprays (trademark: Nazolam / Nasolam) containing midazolam. The EMA recommended authorisation of Nasolam in the EU in January 2022.
Device picture: property and courtesy of Aptar Pharma